Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities
Mastitis has well-recognized harmful effects on dairy farm profitability. Furthermore, mastitis impairs the milk component synthesizing ability of secretary tissues. Various therapies are available for the treatment of clinical mastitis. Meloxicam exhibits preferential binding to Cyclooxygenase-2 (C...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Pharmacy and Bioallied Sciences |
| Subjects: | |
| Online Access: | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2022;volume=14;issue=3;spage=121;epage=125;aulast=Jyothi |
| _version_ | 1811240559958818816 |
|---|---|
| author | Vaskuri G S Satya Sainaga Jyothi Chanti Katta Babu Rahul Kumar Pankaj Kumar Singh Dharmendra Kumar Khatri Shashi Bala Singh Jitender Madan |
| author_facet | Vaskuri G S Satya Sainaga Jyothi Chanti Katta Babu Rahul Kumar Pankaj Kumar Singh Dharmendra Kumar Khatri Shashi Bala Singh Jitender Madan |
| author_sort | Vaskuri G S Satya Sainaga Jyothi |
| collection | DOAJ |
| description | Mastitis has well-recognized harmful effects on dairy farm profitability. Furthermore, mastitis impairs the milk component synthesizing ability of secretary tissues. Various therapies are available for the treatment of clinical mastitis. Meloxicam exhibits preferential binding to Cyclooxygenase-2 (COX-2) receptor and consequently generates fewer negative gastrointestinal side effects than nonspecific COX inhibitors such as flunixin meglumine and ketoprofen. Toward this end, research efforts directed at understanding the use of meloxicam alone and in combination with other antibiotics to improve milk quality and production. Therefore, in this review, we have highlighted the mechanism, biopharmaceutical challenges, and merits of meloxicam usage in dairy cattle mastitis. In addition, we also presented the integration of artificial neural network, in silico docking, and nanotechnology-driven topical drug delivery cargo as future opportunity for efficient delivery of meloxicam in the management of clinical mastitis. |
| first_indexed | 2024-04-12T13:22:22Z |
| format | Article |
| id | doaj.art-f29cd721e11043168bb7cfe904d237e1 |
| institution | Directory Open Access Journal |
| issn | 0975-7406 |
| language | English |
| last_indexed | 2024-04-12T13:22:22Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Pharmacy and Bioallied Sciences |
| spelling | doaj.art-f29cd721e11043168bb7cfe904d237e12022-12-22T03:31:26ZengWolters Kluwer Medknow PublicationsJournal of Pharmacy and Bioallied Sciences0975-74062022-01-0114312112510.4103/jpbs.jpbs_649_21Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunitiesVaskuri G S Satya Sainaga JyothiChanti Katta BabuRahul KumarPankaj Kumar SinghDharmendra Kumar KhatriShashi Bala SinghJitender MadanMastitis has well-recognized harmful effects on dairy farm profitability. Furthermore, mastitis impairs the milk component synthesizing ability of secretary tissues. Various therapies are available for the treatment of clinical mastitis. Meloxicam exhibits preferential binding to Cyclooxygenase-2 (COX-2) receptor and consequently generates fewer negative gastrointestinal side effects than nonspecific COX inhibitors such as flunixin meglumine and ketoprofen. Toward this end, research efforts directed at understanding the use of meloxicam alone and in combination with other antibiotics to improve milk quality and production. Therefore, in this review, we have highlighted the mechanism, biopharmaceutical challenges, and merits of meloxicam usage in dairy cattle mastitis. In addition, we also presented the integration of artificial neural network, in silico docking, and nanotechnology-driven topical drug delivery cargo as future opportunity for efficient delivery of meloxicam in the management of clinical mastitis.http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2022;volume=14;issue=3;spage=121;epage=125;aulast=Jyothiartificial neural networkclinical evidencemastitismeloxicampreclinical evidencetopical drug delivery systems |
| spellingShingle | Vaskuri G S Satya Sainaga Jyothi Chanti Katta Babu Rahul Kumar Pankaj Kumar Singh Dharmendra Kumar Khatri Shashi Bala Singh Jitender Madan Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities Journal of Pharmacy and Bioallied Sciences artificial neural network clinical evidence mastitis meloxicam preclinical evidence topical drug delivery systems |
| title | Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities |
| title_full | Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities |
| title_fullStr | Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities |
| title_full_unstemmed | Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities |
| title_short | Meloxicam in combating clinical mastitis: Nanotechnology-driven hope and opportunities |
| title_sort | meloxicam in combating clinical mastitis nanotechnology driven hope and opportunities |
| topic | artificial neural network clinical evidence mastitis meloxicam preclinical evidence topical drug delivery systems |
| url | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2022;volume=14;issue=3;spage=121;epage=125;aulast=Jyothi |
| work_keys_str_mv | AT vaskurigssatyasainagajyothi meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities AT chantikattababu meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities AT rahulkumar meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities AT pankajkumarsingh meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities AT dharmendrakumarkhatri meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities AT shashibalasingh meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities AT jitendermadan meloxicamincombatingclinicalmastitisnanotechnologydrivenhopeandopportunities |